Nsclc 2nd line
Upcoming SlideShare
Loading in...5
×
 

Like this? Share it with your network

Share

Nsclc 2nd line

on

  • 928 views

 

Statistics

Views

Total Views
928
Views on SlideShare
928
Embed Views
0

Actions

Likes
0
Downloads
31
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Nsclc 2nd line Presentation Transcript

  • 1. Second Line Treatment of metastatic Non-Small Cell Lung Cancer Update from the World Conference on Lung Cancer G. Nsouli MDTuesday, August 9, 2011
  • 2. Tuesday, August 9, 2011
  • 3. Tuesday, August 9, 2011
  • 4. Tuesday, August 9, 2011
  • 5. Weekly vs 3-weekly Docetaxel Overall survival (OAS) curves by treatment arm. Individual Patient Data Meta-Analysis of Docetaxel Administered Once Every 3 Weeks Compared With Once Every Week Second- Line Treatment of Advanced Non– Small-Cell Lung Cancer Di MaioTuesday, August 9, 2011 J.Clin. Oncol.
  • 6. Weekly vs 3-weekly Docetaxel Treatment effect on survival within major patient subgroups. PS, performance status. Individual Patient Data Meta-Analysis of Docetaxel Administered Once Every 3 Weeks Compared With Once Every Week Second- Line Treatment of Advanced Non– Small-Cell Lung Cancer Di MaioTuesday, August 9, 2011 J.Clin. Oncol.
  • 7. Pemetrexed vs. Docetaxel in second line Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non– Small-Cell Lung CancerPreviously Treated With ChemotherapyJ. Clin. Oncol 2004; 22:1589-97Tuesday, August 9, 2011
  • 8. Survival and Toxicity Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non– Small-Cell Lung CancerPreviously Treated With ChemotherapyJ. Clin. Oncol 2004; 22:1589-97Tuesday, August 9, 2011
  • 9. Median time to progression (A) for patients younger than 70 years of age: pemetrexed, 3.0 months v docetaxel, 3.9 months (hazard ratio [HR], 1.03; ; (B) for patients 70 years of age: pemetre-xed, 4.6 months v docetaxel, 2.9 months (HR,Benefit0.72; Elderly Patients From Second-Line Cytotoxic Chemotherapy: A Subset Analysis of a Randomized PhaseIII Trial of Pemetrexed Compared With Docetaxel in Patients With Previously Treated Advanced Non– Small-Cell Lung Cancer Weiss G J.Clin. Oncol. 006;24:4405-11Tuesday, August 9, 2011
  • 10. Median overall survival time (A) for patients younger than 70 years of age: pemetrexed, 7.8 months v docetaxel, 8.0 months HR], 1.02; (B) for patients 70 years of age: pemetrexed, 9.5 months v docetaxel, 7.7 months (HR, 0.86; Patients Benefit Elderly From Second-Line Cytotoxic Chemotherapy: A Subset Analysis of a Randomized PhaseIII Trial of Pemetrexed Compared With Docetaxel in Patients With Previously Treated Advanced Non– Small-Cell Lung Cancer Weiss G J.Clin. Oncol. 006;24:4405-11Tuesday, August 9, 2011
  • 11. Current Guidelines in Second line treatment of NSCLC • For patients with disseminated metastatic disease, both second-line cytotoxic chemotherapy and small molecule epidermal growth factor receptor (EGFR) inhibitors may provide palliation and increase survival. • When symptoms are due to progressive disease within the chest or from metastatic involvement of a single or limited number of sites, radiation therapy (RT) is often useful for palliation.Tuesday, August 9, 2011
  • 12. Tuesday, August 9, 2011
  • 13. Tuesday, August 9, 2011
  • 14. Tuesday, August 9, 2011
  • 15. Tuesday, August 9, 2011
  • 16. Tuesday, August 9, 2011
  • 17. Tuesday, August 9, 2011
  • 18. Tuesday, August 9, 2011
  • 19. Tuesday, August 9, 2011
  • 20. Tuesday, August 9, 2011
  • 21. Tuesday, August 9, 2011
  • 22. Tuesday, August 9, 2011
  • 23. Tuesday, August 9, 2011
  • 24. Tuesday, August 9, 2011
  • 25. Tuesday, August 9, 2011
  • 26. Tuesday, August 9, 2011
  • 27. Tuesday, August 9, 2011
  • 28. Tuesday, August 9, 2011
  • 29. Tuesday, August 9, 2011
  • 30. Tuesday, August 9, 2011
  • 31. Tuesday, August 9, 2011
  • 32. Tuesday, August 9, 2011
  • 33. Tuesday, August 9, 2011
  • 34. Tuesday, August 9, 2011
  • 35. Tuesday, August 9, 2011
  • 36. Tuesday, August 9, 2011
  • 37. Tuesday, August 9, 2011
  • 38. Tuesday, August 9, 2011
  • 39. Tuesday, August 9, 2011
  • 40. Tuesday, August 9, 2011
  • 41. Tuesday, August 9, 2011
  • 42. Tuesday, August 9, 2011
  • 43. Tuesday, August 9, 2011